{'fraction_non_alphanumeric': 0.04113475177304964, 'fraction_numerical': 0.03049645390070922, 'mean_word_length': 4.806584362139918, 'pattern_counts': {'":': 0, '<': 4, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
OP0015 The disease course of patients with rheumatoid arthritis in remission; a prospective 2 year follow-up study

Background Objectives To assess the prevalence of persistent remission and factors associated with persistent remission in a large cohort of RA patients in remission. Methods RA patients in remission according to the ACR/Pinals criteria were evaluated every 3 months for disease activity during 2 years. Factors measured at baseline and possibly associated with persistent remission were evaluated. Results Of the 180 RA patients included 93 (52%) experienced persistent remission. Those patients had significantly (p < 0.05) less tender joints, lower Ritchie score, lower VAS score, lower serum IgM-RF and IgA-RF levels, lower HAQ score at baseline when compared to patients suffering an exacerbation. DMARD use was not associated with persistent remission. In a multivariate analysis, the following variables were independently associated with persistent remission: DAS < 1.6 (odds ratio with 95% CI: 3.7, 1.5–9.5) and VAS < 12 (1.1, 1.0–1.2). The area under the curve of the DAS < 1.6 in the first year was associated with remission in the second year (9.9, 4.1–24). Conclusion Persistent remission occurs frequently and is associated with a low disease activity score (DAS), in particular with a low cumulative DAS. The use of a cumulative DAS may be a tool in taking therapeutic decisions.